Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Compass Therapeutics (CMPX) over the last 2 years, with Sep 2025 value amounting to $129.4 million.

  • Compass Therapeutics' Cash from Financing Activities rose 6468150.00% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.4 million, marking a year-over-year increase of 643.60%. This contributed to the annual value of $17.3 million for FY2024, which is 490.73% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Cash from Financing Activities is $129.4 million, which was up 15,972.52% from -$815,000 recorded in Q1 2025.
  • Over the past 5 years, Compass Therapeutics' Cash from Financing Activities peaked at $129.4 million during Q3 2025, and registered a low of -$815,000 during Q1 2025.
  • In the last 3 years, Compass Therapeutics' Cash from Financing Activities had a median value of $11,000 in 2023 and averaged $14.9 million.
  • As far as peak fluctuations go, Compass Therapeutics' Cash from Financing Activities crashed by 109.52% in 2024, and later surged by 6,468,150.00% in 2025.
  • Quarterly analysis of 3 years shows Compass Therapeutics' Cash from Financing Activities stood at -$158,000 in 2023, then surged by 40.51% to -$94,000 in 2024, then spiked by 6,468,150.00% to $129.4 million in 2025.
  • Its Cash from Financing Activities stands at $129.4 million for Q3 2025, versus -$815,000 for Q1 2025 and -$94,000 for Q4 2024.